Furthermore, a clinical trial with the PDE10A inhibitor 22 (MP-10) in patients with an acute exacerbation of schizophrenia (www.clinicaltrials.gov: NCT01175135) revealed no differences between subjects that received compound 22 and the placebo control group [181]. This evidence concerns the gene PDE10A and schizophrenia.